Understanding disease and treatment in older adults with liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit 84 older adults, aged 65 and above, who have been newly diagnosed with unresectable advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. It utilizes comprehensive geriatric assessment tools to evaluate the unique disease characteristics and treatment patterns in this population. The study will collect data on treatment toxicities and markers of aging to identify barriers to treatment and risk factors for increased morbidity. The findings will inform the development of personalized treatment algorithms for older adults with HCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma.
* Age 18 years and older.
* Patients with advanced, unresectable HCC as determined by the treating physician.

Exclusion Criteria:

* Patients with resectable HCC who are still candidates for locoregional therapy
* Patients receiving prior systemic or locoregional therapy

Where it's running

• Mays Cancer Center
  San Antonio, Texas, United States Recruiting

Study contacts

• Principal investigator: Sukeshi Patel Arora, MD — Mays Cancer Center
• Study coordinator: Maggie Tomasini, MPH
• Email: tomasinim@uthscsa.edu
• Phone: 210-450-0507

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Irpagratinib plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma with FGF19 overexpression

  This trial will test whether adding irpagratinib to atezolizumab and bevacizumab helps people with advanced or unresectable hepatocellular carcinoma whose tumors overexpress FGF19.

  Recruiting Phase 2 Asan Medical Center · Seoul and 2 other locations · NCT07010497

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

• Evaluating HLX43 for advanced liver cancer patients who can't tolerate standard treatments

  This study is testing a new treatment called HLX43 for people with advanced liver cancer who can't handle standard therapies to see if it helps them.

  Recruiting Phase 2 Shanghai Henlius Biotech · Hunan, Hunan · NCT06742892

• Evaluating AST-201 for GPC3-positive advanced solid tumors

  This study is testing a new treatment called AST-201 to see if it can help people with advanced solid tumors that have a specific marker called GPC3.

  Recruiting at 4 sites Phase 1 Aptamer Sciences, Inc. · Goyang-si, Gyeonggi-do and 3 other locations · NCT06687941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.